title: [Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of sorafenib in Chinese patients with advanced renal cell carcinoma.
  
  
  METHODS
  The data of 174 advanced renal cell carcinoma patients orally taking sorafenib in our single center from October 2006 to October 2013 was retrospectively collected. Progression free survival (PFS), overall survival (OS) of these patients and drug-related side effects were analyzed.
  
  
  RESULTS
  Disease control rate was 92% for the whole group. The median PFS of patients taking standard dose (400 mg bid) was (8.0±0.6) months, the median PFS of patients taking increased dose (600 mg bid) after progression was (5.0±1.0) months, the median PFS of patients taking increased dose (800 mg bid) after second-progression was (2.0±0.4) months. The median OS was (24.0±2.8) months. The common side effects included hand-foot reaction (70%), fatigue (57.4%), diarrhea (45.2%), rash (39.9%) and hypertension (21.8%).
  
  
  CONCLUSIONS
  Sorafenib has good efficacy and safety in Chinese patients with advanced renal cell carcinoma. Increased dose could bring clinical benefit after standard dose failed.
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Bixia
authors.initials: B
authors.lastname: Tang
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Chi
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xinan
authors.initials: X
authors.lastname: Sheng
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Chuanliang
authors.initials: C
authors.lastname: Cui
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Si
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Kong
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Siming
authors.initials: S
authors.lastname: Li
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Mao
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Lian
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Wang
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xieqiao
authors.initials: X
authors.lastname: Yan
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China; Email: guoj307@126.com.
authors.forename: Jun
authors.initials: J
authors.lastname: Guo
mesh_terms: D000970:Antineoplastic Agents; D002292:Carcinoma, Renal Cell; D003967:Diarrhea; D018572:Disease-Free Survival; D005221:Fatigue; D006801:Humans; D007680:Kidney Neoplasms; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D012189:Retrospective Studies; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib